Dr. Howard Smith Oncall

  Vidcast:  https://youtu.be/7VEwuryRJ7Y   The FDA just granted an emergency use authorization, the prized EUA, for Lilly’s IgG1 monoclonal antibody called Bamlanivimab.  This now joins the  Regeneron dual antibody cocktail as early treatment for CoVid.   Thing is, though, there are many catch-22s about bamlanivimab.  It must be given immediately after symptom onset when patients are at their most contagious and a danger to others.  It’s not for hospitalized patients or for those requiring oxygen.  Bamlanivimab requires 3 hours for IV infusion, its tricky to prepare and requires refrigeration, and it has serious side effects like anaphylaxis.  The worst problem: it’s in short supply and there’s only about 2 week’s worth in existence.   https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19   https://blogs.jwatch.org/hiv-id-observations/index.php/bamlanivimab-hard-to-pronounce-even-harder-to-give/2020/11/15/   #covid #bamlanivimab